Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studiesFrank R. Brennan, David P. Humphreys, Babette Wolf et al.|mAbs|2025Cited by 30
Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC)Mineo Matsumoto, Jean G. Sathish, Joseph Ryan Polli et al.|Clinical Pharmacology & Therapeutics|2024Cited by 15